Larazotide (AT-1001): 10mg

Description

Larazotide acetate (at-1001) is a synthetic 8-amino acid peptide derived from vibrio cholerae zona occludens toxin (zot) that acts as a tight junction regulator — the most specific peptide tool available for intestinal barrier research. larazotide's mechanism is precise: it blocks the action of zonulin — the endogenous protein that triggers tight junction disassembly and increases intestinal permeability ('leaky gut') — by competitively inhibiting zonulin receptor binding on intestinal epithelial cells. unlike compounds that repair existing tissue damage, larazotide acts at the structural barrier level, preventing the paracellular leakage of antigens, pathogens, and toxins that drives gut-systemic inflammation. phase 2 clinical trials demonstrated significant reduction in intestinal permeability markers, anti-gliadin antibody levels, and gastrointestinal symptoms in celiac disease patients. separate trials in non-celiac ibd populations showed favorable safety and symptom improvement. larazotide is the structural component of the gut healing stack, where it works alongside kpv (melanocortin receptor-mediated mucosal anti-inflammation) and bpc-157 oral tablets (vegfr2-driven tissue repair) to address all three foundational layers of gut dysfunction simultaneously. all-oral administration targets the intestinal lining directly. for research and educational purposes only.

Specifications

Dose Calculator